Severe skin reaction secondary to concomitant radiotherapy plus cetuximab.
The therapeutic use of monoclonal antibodies against the epidermal growth factor receptor (EGFR) is specifically associated with dermatologic reactions of variable severity. Recent evidence suggests superiority of the EGFR inhibitor (EGFRI) cetuximab plus radiotherapy compared to radiotherapy alone in patients with squamous cell carcinoma of the head and neck. Although not documented in a study population, several reports indicate a possible overlap between radiation dermatitis and the EGFRI-induced skin rash. We here present a case of severe skin reaction secondary to the addition of cetuximab to radiotherapy.
Berger
Bernhard
B
Department of Radiation Oncology, University of Tübingen, Germany. bernhard.berger@med.uni-tuebingen.de
Belka
Claus
C